MeSH term
Frequency | Condition_Probility | *Gene Amplification | 34 | 8.0 |
Gene Expression Regulation, Neoplastic | 19 | 0.0 |
Genes, bcl-1/*genetics | 9 | 75.0 |
Humans | 223 | 0.0 |
*Papillomavirus, Human | 2 | 6.0 |
Prognosis | 43 | 0.0 |
Risk Factors | 9 | 0.0 |
Blotting, Northern | 8 | 0.0 |
Cyclin D1/*genetics | 42 | 68.0 |
Gene Expression Profiling | 6 | 0.0 |
*Genes, Tumor Suppressor | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 12 | 1.0 |
Research Support, Non-U.S. Gov't | 163 | 0.0 |
Transfection | 4 | 0.0 |
Tumor Cells, Cultured | 19 | 0.0 |
*Tumor Suppressor Proteins | 5 | 0.0 |
Chromosome Aberrations | 9 | 1.0 |
In Situ Hybridization, Fluorescence/*methods | 4 | 4.0 |
Gene Dosage | 12 | 3.0 |
Genes, Tumor Suppressor | 6 | 0.0 |
Multigene Family | 2 | 0.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Oncogenes | 3 | 1.0 |
Polymerase Chain Reaction | 29 | 0.0 |
Adult | 60 | 0.0 |
Aged | 73 | 0.0 |
Aged, 80 and over | 38 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
Case-Control Studies | 16 | 0.0 |
DNA, Neoplasm/analysis | 11 | 1.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Female | 118 | 0.0 |
*Genes, cdc | 2 | 9.0 |
Male | 87 | 0.0 |
Middle Aged | 86 | 0.0 |
Neoplasm Proteins/genetics | 4 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
*Proto-Oncogene Proteins | 9 | 0.0 |
Blotting, Southern | 18 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 7 | 3.0 |
Chromosomes, Human, Pair 14/genetics | 2 | 2.0 |
Comparative Study | 33 | 0.0 |
DNA, Neoplasm/genetics | 7 | 0.0 |
Immunohistochemistry | 34 | 0.0 |
In Situ Hybridization, Fluorescence | 33 | 1.0 |
Lymphoma, Mantle-Cell/genetics/metabolism/*pathology | 2 | 66.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 17 | 0.0 |
Translocation, Genetic | 9 | 1.0 |
*Chromosomes, Human, Pair 13 | 2 | 1.0 |
*Chromosomes, Human, Pair 14 | 9 | 4.0 |
*Gene Deletion | 3 | 0.0 |
*Genes, Immunoglobulin | 2 | 1.0 |
*Translocation, Genetic | 14 | 1.0 |
*Chromosomes, Human, Pair 11 | 24 | 3.0 |
DNA Probes | 4 | 0.0 |
In Situ Hybridization, Fluorescence/methods | 3 | 3.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Gene Frequency | 4 | 0.0 |
Genetic Markers | 8 | 0.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Genotype | 20 | 0.0 |
*Polymorphism, Genetic | 11 | 0.0 |
Carcinoma, Squamous Cell/*genetics/metabolism | 5 | 19.0 |
Cyclin D1/metabolism | 4 | 2.0 |
Gene Expression | 11 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Ovarian Neoplasms/*genetics/metabolism | 2 | 5.0 |
Research Support, U.S. Gov't, P.H.S. | 44 | 0.0 |
*Trans-Activators | 2 | 0.0 |
Biopsy | 4 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 15 | 6.0 |
Cyclin D1/*genetics/metabolism | 8 | 42.0 |
Gene Amplification | 23 | 3.0 |
Head and Neck Neoplasms/*genetics/metabolism | 4 | 57.0 |
*Gene Rearrangement | 7 | 2.0 |
Models, Genetic | 3 | 0.0 |
Time Factors | 4 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
DNA Primers/chemistry | 4 | 0.0 |
Genetic Predisposition to Disease | 7 | 0.0 |
Polymorphism, Genetic | 11 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 13 | 7.0 |
Cluster Analysis | 3 | 1.0 |
DNA, Neoplasm/*genetics | 3 | 1.0 |
Genes, myc/genetics | 2 | 2.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
Neoplasm Proteins/*genetics | 8 | 0.0 |
Oligonucleotide Array Sequence Analysis/methods | 4 | 4.0 |
RNA, Messenger/analysis | 5 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Age Factors | 2 | 0.0 |
Alleles | 9 | 0.0 |
Alternative Splicing | 4 | 0.0 |
Bladder Neoplasms/*genetics | 4 | 4.0 |
Odds Ratio | 2 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Risk | 3 | 0.0 |
Sex Factors | 2 | 0.0 |
Receptors, Estrogen/analysis | 3 | 0.0 |
Reference Values | 2 | 0.0 |
Survival Rate | 6 | 0.0 |
*Gene Expression Profiling | 4 | 0.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Up-Regulation | 6 | 0.0 |
Genes, bcl-1 | 3 | 23.0 |
Loss of Heterozygosity | 4 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Phosphoric Monoester Hydrolases/genetics | 2 | 2.0 |
Child | 7 | 0.0 |
*Gene Expression Regulation, Neoplastic | 7 | 0.0 |
Neoplasms/*genetics | 3 | 1.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
RNA, Complementary/metabolism | 2 | 8.0 |
Chromosomes, Human, Pair 11 | 13 | 3.0 |
Chromosomes, Human, Pair 14 | 3 | 1.0 |
Cyclin D1/genetics | 14 | 22.0 |
Immunophenotyping | 6 | 0.0 |
Base Sequence | 18 | 0.0 |
Cell Differentiation | 2 | 0.0 |
DNA Primers | 6 | 0.0 |
Cyclin D1/biosynthesis/genetics | 5 | 26.0 |
Estrogen Receptor alpha | 4 | 1.0 |
Proteins/genetics | 2 | 0.0 |
RNA, Neoplasm/biosynthesis | 3 | 2.0 |
Animals | 21 | 0.0 |
*Chromosome Aberrations | 9 | 1.0 |
Mice | 14 | 0.0 |
Organ Specificity | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Chromosome Mapping | 18 | 0.0 |
Genome, Human | 2 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Disease Progression | 7 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 2 | 1.0 |
Paraffin Embedding | 4 | 1.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 3 | 5.0 |
Carcinoma, Ductal, Breast/genetics/metabolism/pathology | 3 | 25.0 |
Carcinoma, Lobular/genetics/metabolism/pathology | 2 | 33.0 |
Cohort Studies | 3 | 0.0 |
Neoplasm Invasiveness/genetics/pathology | 2 | 40.0 |
Retrospective Studies | 10 | 0.0 |
Apoptosis | 3 | 0.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 5 | 7.0 |
Cell Cycle | 5 | 0.0 |
Cell Division | 2 | 0.0 |
Head and Neck Neoplasms/*genetics/pathology | 4 | 13.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Breast Neoplasms/*genetics | 13 | 1.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
*Mutation | 4 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Exons | 3 | 0.0 |
Introns | 3 | 0.0 |
Neoplasm Staging | 15 | 0.0 |
Cyclin D1/*genetics/*metabolism | 2 | 66.0 |
Sex Characteristics | 2 | 0.0 |
Aneuploidy | 4 | 2.0 |
DNA, Neoplasm | 3 | 2.0 |
English Abstract | 6 | 0.0 |
Head and Neck Neoplasms/*genetics | 7 | 9.0 |
Oncogenes/*genetics | 5 | 6.0 |
Carcinoma, Hepatocellular/*genetics | 2 | 2.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Nucleic Acid Hybridization/*methods | 4 | 8.0 |
Oligonucleotide Array Sequence Analysis/*methods | 2 | 1.0 |
*Oncogenes | 8 | 1.0 |
Antibodies, Monoclonal/diagnostic use | 2 | 0.0 |
Cyclin D1/*metabolism | 7 | 11.0 |
Diagnosis, Differential | 4 | 0.0 |
Data Interpretation, Statistical | 2 | 0.0 |
Flow Cytometry | 7 | 0.0 |
Laryngeal Neoplasms/genetics | 2 | 15.0 |
Nucleic Acid Amplification Techniques | 3 | 7.0 |
Oncogenes/genetics | 2 | 2.0 |
Prospective Studies | 3 | 0.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Rats | 4 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
Proto-Oncogene Proteins/genetics | 7 | 1.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Genes, erbB-2 | 7 | 8.0 |
Heterozygote | 2 | 0.0 |
Mutation | 9 | 0.0 |
Age of Onset | 2 | 0.0 |
Survival Analysis | 10 | 0.0 |
Cell Cycle/genetics | 3 | 2.0 |
Cell Division/genetics | 3 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Mice, Nude | 3 | 0.0 |
Signal Transduction | 2 | 0.0 |
Species Specificity | 3 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Cell Line | 4 | 0.0 |
Cell Transformation, Neoplastic/genetics | 4 | 1.0 |
Cyclin D1/biosynthesis/*genetics | 4 | 66.0 |
Molecular Sequence Data | 17 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Tumor Markers, Biological | 3 | 0.0 |
Colonic Neoplasms/*genetics | 2 | 2.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 2 | 0.0 |
*Zebrafish Proteins | 2 | 0.0 |
Immunoglobulins, Heavy-Chain/genetics | 3 | 1.0 |
Karyotyping | 8 | 0.0 |
Neoplasm Recurrence, Local/genetics/pathology | 3 | 30.0 |
Translocation, Genetic/*genetics | 4 | 1.0 |
Variation (Genetics) | 2 | 0.0 |
Blotting, Western | 3 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
Mice, SCID | 2 | 0.0 |
Neoplasm Transplantation | 2 | 0.0 |
Cyclin D1/*biosynthesis | 2 | 10.0 |
*Aneuploidy | 2 | 2.0 |
*Loss of Heterozygosity | 4 | 1.0 |
Cell Line, Tumor | 5 | 0.0 |
Receptors, Estrogen/*metabolism | 2 | 0.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Interphase | 2 | 1.0 |
Sensitivity and Specificity | 4 | 0.0 |
Genes, Retinoblastoma | 2 | 2.0 |
Genes, myc | 5 | 1.0 |
*In Situ Hybridization, Fluorescence | 4 | 2.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
Glutathione Transferase/*genetics | 2 | 0.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
*Microfilament Proteins | 3 | 6.0 |
Combined Modality Therapy | 2 | 0.0 |
Follow-Up Studies | 4 | 0.0 |
*Proto-Oncogenes | 3 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Carcinogens | 2 | 2.0 |
Cyclin-Dependent Kinases/*genetics | 3 | 4.0 |
*Genes, Retinoblastoma | 3 | 2.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Adolescent | 5 | 0.0 |
Japan | 2 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
*Nuclear Proteins | 2 | 0.0 |
Phenotype | 5 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 2 | 0.0 |
Cyclins/*metabolism | 2 | 0.0 |
*Cell Cycle Proteins | 5 | 0.0 |
Cyclin D1/biosynthesis | 3 | 7.0 |
Cyclin D1/*analysis/genetics | 2 | 66.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 4 | 28.0 |
Laryngeal Neoplasms/*genetics/mortality/pathology | 2 | 40.0 |
Receptors, Estrogen/*analysis | 2 | 0.0 |
Cyclin D1/*biosynthesis/*genetics | 2 | 66.0 |
In Situ Hybridization | 5 | 0.0 |
Cyclins/*biosynthesis/*genetics | 2 | 66.0 |
Breast Neoplasms/*genetics/metabolism | 3 | 2.0 |
Carcinoma, Ductal, Breast/*genetics/metabolism | 2 | 22.0 |
*Genes, bcl-1 | 2 | 66.0 |
Immunoenzyme Techniques | 4 | 0.0 |
Receptors, Estrogen/metabolism | 4 | 1.0 |
Lymphoma, Small Cleaved-Cell, Diffuse/*genetics | 2 | 33.0 |
*Gene Expression | 2 | 0.0 |
Multiple Myeloma/*genetics | 4 | 9.0 |
DNA, Viral/analysis | 3 | 0.0 |
Breast Neoplasms/*genetics/mortality/pathology | 2 | 25.0 |
Fibroblast Growth Factors/genetics | 3 | 7.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
DNA, Neoplasm/isolation & purification | 2 | 6.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Head and Neck Neoplasms/*genetics/mortality/pathology | 2 | 40.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Chromosomes, Human, Pair 14/*genetics | 2 | 2.0 |
Reproducibility of Results | 2 | 0.0 |
Chromosomes, Human, Pair 17/genetics | 2 | 1.0 |
Lymphoma, B-Cell/*genetics | 2 | 2.0 |
Monosomy | 2 | 6.0 |
Trisomy | 2 | 1.0 |
Gene Amplification/*genetics | 11 | 10.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Breast Neoplasms/*genetics/pathology | 6 | 2.0 |
Chromosome Deletion | 2 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Cell Cycle/physiology | 2 | 0.0 |
Carrier Proteins/*genetics | 4 | 0.0 |
Gene Deletion | 6 | 0.0 |
Protein p16/*genetics | 2 | 2.0 |
*Alleles | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Chromosome Banding | 2 | 0.0 |
Lymphoma, Large-Cell, Diffuse/*genetics | 2 | 8.0 |
Bone Marrow/pathology | 2 | 0.0 |
*Genes, p16 | 3 | 3.0 |
Genes, p53 | 2 | 0.0 |
Esophageal Neoplasms/*genetics | 3 | 4.0 |
Cyclin D1 | 29 | 21.0 |
Cyclins/genetics | 2 | 1.0 |
Genes, ras | 2 | 0.0 |
Oncogene Proteins/genetics | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
Multicenter Studies | 2 | 1.0 |
Cyclins/*genetics | 19 | 13.0 |
Oncogene Proteins/*genetics | 16 | 11.0 |
Lymphoma, Mantle-Cell/*genetics/pathology | 2 | 50.0 |
Cyclins/*genetics/metabolism | 5 | 11.0 |
Lymphatic Metastasis | 4 | 0.0 |
Consensus Sequence | 2 | 0.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
Oncogene Proteins/*genetics/metabolism | 4 | 18.0 |
Cyclins/analysis/*genetics | 2 | 50.0 |
Oncogene Proteins/analysis/*genetics | 2 | 33.0 |
Genes, p53/*genetics | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics | 5 | 0.0 |
Cyclin D1/analysis/*genetics | 3 | 60.0 |
Endometrial Neoplasms/*genetics | 2 | 4.0 |
Homozygote | 3 | 0.0 |
Protein p16 | 3 | 2.0 |
Adenoma, Oxyphilic/*genetics | 2 | 50.0 |
Kidney Neoplasms/*genetics | 2 | 0.0 |
Molecular Probes | 2 | 3.0 |
Carcinoma/genetics/pathology | 2 | 9.0 |
Proto-Oncogenes | 2 | 1.0 |
Gene Rearrangement | 5 | 1.0 |
Carcinoma, Squamous Cell/chemistry/*genetics/pathology | 2 | 40.0 |
Head and Neck Neoplasms/chemistry/*genetics/pathology | 2 | 66.0 |
Lymphoma, Small Cleaved-Cell, Diffuse/genetics/*metabolism | 2 | 100.0 |
Esophageal Neoplasms/*genetics/pathology | 3 | 9.0 |
Restriction Mapping | 3 | 0.0 |
Prostatic Neoplasms/*genetics/pathology | 2 | 2.0 |
Cytogenetics | 2 | 2.0 |
Protein p53/metabolism | 2 | 0.0 |
Gene Expression Profiling/methods | 3 | 4.0 |
Lymphoma, Non-Hodgkin/*genetics | 3 | 7.0 |
Cells, Cultured | 2 | 0.0 |
Cyclins/*biosynthesis | 2 | 3.0 |
Oncogene Proteins/*biosynthesis | 2 | 11.0 |
Adenoma/*genetics | 2 | 2.0 |
Gene Expression Regulation | 2 | 0.0 |
Point Mutation | 2 | 0.0 |
Cyclin D1/analysis | 2 | 5.0 |
Gene Expression Regulation, Neoplastic/*genetics | 2 | 1.0 |
Colorectal Neoplasms/epidemiology/*genetics | 2 | 15.0 |
Methylation | 2 | 0.0 |
Carcinoma/*genetics | 2 | 1.0 |
Metaphase | 3 | 2.0 |
Ovarian Neoplasms/*genetics | 2 | 0.0 |
DNA Repair | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Biopsy, Needle | 2 | 0.0 |
Genes, myc/*genetics | 2 | 2.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
